بررسی سطح کیفیت زندگی بیماران مبتلا به ملاسما مراجعه کننده به درمانگاه پوست بیمارستان رازی تهران و ارزیابی شدت بیماری آنها


۱ بهمن ۱۳۹۶

ملاسما يك هيپرپيگمانتاسيون قرينه اكتسابي قهوه اي رنگ بر روي صورت يا گردن مي باشد كه تأثيرات واضح احساسي و رواني بر بيماران مب تلا دارد . با وجود اينكه اين بيماري در زنان به ويژه در سنين باروري شيوع دارد تأثير آن بر كيفيت زندگي اين جمعيت به خوبی شناخته شده نیست. بنابراین هدف اصلی تحقیق حاضر بررسی سطح کیفیت زندگی بیماران مبتلا به ملاسما مراجعه کننده به درمانگاه پوست بیمارستان رازی تهران و ارزیابی شدت بیماریشان است.

روش اﺟﺮا : اﻳﻦ ﻣﻄﺎﻟﻌﻪ ازنظر هدف کاربردی می باشد و از نطر روش ﻧﻮع ﻣﻘﻄﻌﻲ ﺑﻮده و ﺑﺎ اﻧﺠﺎم ﻣﻌﺎﻳﻨﻪ ي ﺑﺎﻟﻴﻨﻲ و ﺗﻜﻤﻴﻞ ﭘﺮﺳﺶ ﻧﺎﻣﻪ روي 100 ﺑﻴﻤﺎر ﻣﺒﺘﻼ ﺑـﻪ ﻣﻼﺳـﻤﺎ اﻧﺠـﺎم ﺷـﺪ.ﺟﻬـﺖ ﺑﺮرﺳـﻲ ﺷـﺪت ﻣﻼﺳـﻤﺎ از ﺷـﺎﺧﺺ MASI (Melasma Area and Severity Index) و ﺑﺮاي ارزﻳﺎﺑﻲ ﻛﻴﻔﻴﺖ زﻧﺪﮔﻲ از ﭘﺮﺳﺶ ﻧﺎﻣﻪ ي ( DLQI (Dermatology Life Quality Index) سنجش کیفیت زﻧﺪﮔﻲ در ﺑﻴﻤﺎري ﻫﺎي ﭘﻮﺳﺖ استفاده شده است. 

یافته ها: نتایج نشان میدهد که ارﺗﺒﺎط ﻣﻌﻨﺎدار ﺑﻴﻦ ﻧﻤﺮات ﭘﺮﺳﺶ ﻧﺎﻣﻪ ﻫﺎي ﻛﻴﻔﻴﺖ زﻧﺪﮔﻲ و ﺷﺎﺧﺺ ﺷﺪت ﺑﻴﻤﺎري ﻣﺸﺎﻫﺪه ﺷﺪ (P<0.001). بر اساس نتایج به دست آمده تاثیر تیرگی بیشینه (577/0) بیشتر از تاثیر MASI (510/0) در کیفیت زندگی می باشد. علاوه بر این این نتایج نشان میدهد که تمامی شاخص های DQLI به صورت معناداری تحت تاثیر MASI می باشد چرا که در تمامی حالت ها Sig<0.05 است.

نتیجه گیری: ﻣﻼﺳﻤﺎ ﺑﻪ وﺿﻮح ﺑﺮ ﻛﻴﻔﻴﺖ زﻧﺪﮔﻲ ﻣﺒﺘﻼﻳﺎن ﺗﺄﺛﻴﺮ داﺷﺘﻪ از اﻳـﻦ رو ﭘﺰﺷـﻚ ﻣﻌـﺎﻟﺞ ﻋﻼوه ﺑﺮ درﻣﺎن ﻫﺎي داروﻳﻲ و ﻓﻴﺰﻳﻜﻲ ﺑﺎﻳﺴﺘﻲ ﺑﻪ ﺗـﺄﺛﻴﺮ ﻣﺨـﺮب رواﻧـﻲ ـ اﺟﺘﻤـﺎﻋﻲ اﺧـﺘﻼﻻت رﻧﮓ داﻧﻪاي ﻧﻴﺰ ﺗﻮﺟﻪ نماید.

 

كليد واژه ها : ملاسما، DLQI، MASI، کیفیت زندگی، بیمارستان پوست رازی، شدت بیماری.

مشخصات دانشجو:

نام:  رضا الماسی قلعه

رشته تحصيلي:  پزشکی

مقطع: پزشکی عمومی

گروه آموزشي: پوست

پست الكترونيك دانشجو: reza.almasi_gh@yahoo.com

اساتيد راهنما و داور:

اساتید راهنما: دکتر مریم نسیمی، دکتر حسن صیرفی

اساتيد مشاور: دکتر ربابه عابدینی، دکتر وحیده سادات لاجوردی

اساتيد داور: دکتر ارغوان عزیزپور، دکتر حمیدرضا محمودی

زمان دفاع :

 روز: یکشنبه

 تاريخ : 24/10/1396

ساعت: 12 ظهر

مكان دفاع به آدرس: میدان حسن آباد، خیابان حکمت اسلامی، بیمارستان پوست رازی، ساختمان آموزش، طبقه ی بالای همکف، کتابخانه.

اطلاعات به زبان انگليسي

Title: The evaluation of quality of life in patients suffering from melasma referring to Tehran Razi Hospital dermatology clinic and evaluation of the severity of their disease.

 

Abstract:

Background and goals: Melasma is an acquired hyperpigmentation of brown color on the face or neck, with clear emotional and psychological effects on patients. Although the disease is prevalent in women, especially in reproductive ages, its impact on the quality of life of this population is unknown. Therefore, the main goal of this study was to assess the quality of life of patients with melasma referred to the Dermatology Clinic of Razi Hospital in Tehran and to evaluate the severity of their disease.

Methods: This is a descriptive-objective study. The aim of this study was to investigate the effect of melasma on MASI and to assess the quality of life of the questionnaire by performing a clinical examination and completing a questionnaire on 100 patients with melasma. DLQI (Dermatology Life Quality Index) is used to measure the quality of life in skin diseases.

Results: The results showed that there was a significant relationship between the scores of quality of life questionnaires and the severity index (P <0.001). Based on the results, the effect of maximum darkness (0.577) is greater than the effect of MASI (0.51) on quality of life. In addition, these results show that all DQLI indices are significantly influenced by MASI, since in all modes Sig <0.05.

Conclusion: Melasma clearly affects the quality of life of patients. Therefore, physicians should pay attention to the psychosocial damages of colored dyestuffs in addition to their physiological and physical therapies.

Keywords: DLQI, Melasma, MASI Score, Quality of life, Tehran Razi Hospitatl

 

فهرست منابع و ماخذ فارسي و لاتين:

منابع

  1. صافي زاده حسین، كيفيت زندگي در زنان مبتلا به ملاسما،مجله ی پوست و زيبايي، زمستان 1389 ، دوره ي 1، شماره ي4˛صفحه ی 1-4
  2. Marta Rendon.Treatment of melisma. Journal of american academy of dermatology. 2006 may;:5272-528
  3. Situm M. Melasma-updated treatments. Collegium Antropologicum. 2011 September;35 Suppl 2: page315-318.
  4. Cestari T.F. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. British Journal Dermatology 2007;˛29 (suppl. 1): 13–20
  5. Freitag FM. Effect of melasma on quality of life in a sample of women living in southern Brazil. Journal of European Academy of Dermatology Venereology . 2008 Jun;22(6):655-62
  6. Pichardo R. The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. Internal Journal Dermatol. 2009 Jan;48(1):22-6
  7. 7. Dogramaci AC. Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study. Journal of Dermatological Treatment. 2009 Jun;20(2):90-95
  8. . Cestari T.Melasma in Latin America: options for therapy and treatment algorithm. Journal European Academy Dermatology and Venereologoy. 2009 Jul;23(7): 760-72
  9. Amit G. Pandya. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. Jurnal of American Academy of Dermatology. 2010 Apr;64(1): 78-83
  10. Newcomer VD, Lindbert MC, Stenbert TH. A melanosis of the face (chloasma). Arch Dermatol 2001; 83: 284-97.
  11. Fitzpatrick TB, Eisen AZ, Wolff K, et al (eds). Dermatology in general medicine. New York: McGraw-Hill, 2007; 996-97.
  12. Sanchez NP, Pathak MA, Sato A, et al. Melasma: A clinical, light microscopic, ultrastructural and immunofluorscence study. J Am Acad Dermatol 2005; 131: 1453-1546.
  13. Hughes BR. Melasma occurring in twin sisters. J Am Acad Dermatol 2013; 17: 841.
  14. عدالتخواه ح .ارتباط ملاسما با کيست هاي تخمداني و هورمون هاي جنسي. فصلنامه بيماري هاي پوست ١٣٨١؛ ٦: ١٩-١٤.
  15. Snell RS, Bischitz PG. The effect of large doses of estrogen and progesterone on melanin pigmentation. J Invest Dermatol 2010; 35: 73-81.
  16. Snell RS, Clive D. The pigmentary changes occurring in the breast skin during pregnancy and following estrogen treatment. J Invest Dermatol 2004; 43: 181-86.
  17. Mackie RM. Melanocgtic naevi and malignant melanoma. In: Champion RH, Burton JL, Burns DA, Breathnach SM (eds). Rook/ Wilkinson /Ebling text book of dermatology. Oxford: Blackwell, 2008: 1717-1815.
  18. MacKie RM, English J, Aitchisan TC, et al. The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol 1985; 113: 167-74.
  19. Nicholls EM. Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 2003; 32: 191-95.
  20. Green A, Siskind V, Hansen ME, et al. Melanocytic nevi in schoolchildren in Queensland. J Am Acad Dermatol 2009; 20: 1054-60.
  21. Easton DF, Cox GM, Macdonald AM, Ponder BA. Genetic susceptibility to naevi-a twin study. Br J Cancer 2011; 64: 1164-67.
  22. 13-Kopf AW, et al. Prevalence of nevocytic nevi on lateral and medial aspects of arms. J Dermatol Surg Oncol 2008; 4: 153-58.
  23. Goldman L, Richfield DF. Effect of corticotrophin and cortisone on development and progress of pigmented nevi. JAMA1951; 147: 941-43.
  24. 15-Shoji T, Cockerell J, Koff AB, Bhawan J. Eruptive melanocytic nevi after Stevens- Johnson syndrome. J Am Acad Dermatol 2007: 37: 337-39.
  25. Hughes BR, Cunliffe WJ, Bailey CC. Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ2009; 299: 88-91.
  26. de Wit PE, de Vaan GA, de Boo TM, et al. Prevalence of naevocytic naevi after chemotherapy for childhood cancer. Med Pediatr Oncol 2008: 18: 336-38.
  27. Grob JJ, Bastuji-Garin S, Vaillant C, et al. Excess of nevi related to immunodeficiency. A study in HIV-infected patients and renal transplant recipients. J Invest Dermatol 2006; 107: 694-97.
  28. Pierard GE, Pierard-Franchimont C, Nickels A, et al. Naevocyte triggering by recombinant human growth hormone. J Pathol 2006; 180: 74-79.
  29. Coskey RJ. Eruptive nevi. Arch Dermatol 2005; 111: 1658.
  30. Eady RA, Gilkes JJ, Jones EW. Eruptive nevi. Report of two cases, with enzyme histochemical,light and electron microscopical findings. Br J Dermatol 2007; 97: 267-78.
  31. Cockerell CJ, Johnson TM, Swanson NA. Melonocytic nevi. In: Arndt KA, LeBoit P, Robinson JK, Wintroub B (eds). Cutaneous medicine and surgery. Philadelphia: Saunders, 2006:1561-75.
  32. Brues AM. Linkage of body build with sex, eye color and freckling. Am J Hum Genet 2003; 2: 215-39.
  33. MosherDB, FitzpatrickTB, Ortonne JP, HoriY. Normal skin color and general considerations of pigmentory disorders. In: Freedberg IM, Eisen AZ, Wolff K (eds). Dermatology in general medicine.New York: McGraw- Hill;2009:936-1059.
  34. Victor FC, Gelber J, Rao B. Melasma: A review. J Cutan Med Surg 2004; 8: 97-102.
  35. Jadotte YT, Schwartz RA. Melasma: Insights and perspectives. Acta Dermatovenerol Croat 2010; 18: 124-9.
  36. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a healthrelated quality of life instrument for women with melasma. Br J Dermatol 2003; 149: 572-7.
  37. Damoa AS, Lambert WC, Schwartz RA. Melasma: Insight into a distressing dyschromia. Aesthet Dermatol 2006; 8: 1-6.
  38. Cestari TF, Hexsel D, Viegas ML, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQol-BP study and improvement of Qol of melasma patients after triple combination therapy. Br J Dermatol 2007; 156 (suppl. 1): 13-20.
  39.  Balkrishnan R, McMichael AJ, Hu JY, et al. Correlates of health-related quality of life in women with severe facial blemishes. Int J Dermatol 2006; 45: 111-5.
Dominguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in Latina patients: Crosscultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol 2006; 55: 59-66


منبع: معاونت پژوهشي دانشکده پزشکي